Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2017 > Volume 26 Number 6 November 2017 > MITRAL VALVE DISEASE > Survival Advantage of MitraClip® Over Medical Treatment in Patients with Mitral Regurgitation: A Meta-Analysis

Survival Advantage of MitraClip® Over Medical Treatment in Patients with Mitral Regurgitation: A Meta-Analysis

Tomás Benito-González1, Rodrigo Estévez-Loureiro1, Ignacio Iglesias-Gárriz1, Javier Gualis2, Armando Pérez de Prado1, Carmen Garrote1, Martin J. Swaans3, Jan A. S. Van der Heyden3, Ted Feldman4, Cristina Giannini5, David Alonso1, Miguel Rodriguez-Santamarta1, Mario Castaño2, Felipe Fernández-Vázquez1

1Department of Cardiology, University Hospital of León, León, Spain
2Department of Cardiac Surgery, University Hospital of León, León, Spain
3Department of Cardiology, St. Antonius Hospital, Nieuwegein, Netherlands
4Cardiology Division, Evanston Hospital, NorthShore University Health System, Evanston, Illinois, USA
5Cardiac, Thoracic and Vascular Department, Azienda Ospedaliero-Universitaria, Pisa, Italy
6Electronic correspondence:

Background and aim of the study: The MitraClip® system is a percutaneous treatment for mitral regurgitation (MR) that has shown promising results in patients who are inoperable or at high risk for mitral surgery. Data on the efficacy of the system over optimal medical therapy, above all in patients with functional MR, are scarce. The study aim was to assess the effect of MitraClip on the survival of patients with moderate/severe or severe MR compared to medical therapy, using meta-analytical techniques.

Methods: Independently, reviewers searched electronically for relevant articles based on predefined criteria and end-points. Only articles with a comparison between MitraClip and conservative therapy were included. Standard meta-analysis techniques were used. The primary outcomes were 30-day and one-year mortalities.

Results: Five observational reports were included that enrolled a total of 1,271 patients: 720 patients underwent

percutaneous mitral valve repair (PMVR) with the MitraClip device, and 551 were managed conservatively. A total of 49 all-cause mortality events was reported at 30 days: 3.05% (22/720) in the PMVR arm, and 4.90% (27/510) in the conservative group, with no significant differences in all-cause mortality (OR 0.64; 95% CI 0.36-1.14). A total of 269 all-cause mortality events at one year was reported: 15.14% (109/720) in the PMVR arm, and 29.04% (160/551) in the conservative group. A significant difference favoring PMVR with the MitraClip system over medical therapy alone was observed (OR 0.44; 95% CI 0.30–0.64, p <0.0001). Neither significance between study heterogeneity (p = 0.18) nor publication bias was detected (p = 0.3).

Conclusion: PMVR with the MitraClip system may be associated with an improvement in one-year survival compared to stand-alone medical management.

The Journal of Heart Valve Disease 2017;26:651-658

Survival Advantage of MitraClip® Over Medical Treatment in Patients with Mitral Regurgitation: A Meta-Analysis

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.